Dermipred

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermipred

Quick Facts Overview

Property Description
Active ingredient Prednisolone
Form Oral tablet
Pharmacological class Glucocorticoid (Corticosteroid)
Common use Systemic anti-inflammatory and immunosuppressant
Origin Synthetic

What is Dermipred and What Class of Medicine is It?

Dermipred is a prescription-only veterinary medicinal product whose active pharmaceutical ingredient is prednisolone, which is administered as an oral tablet intended for systemic use. Prednisolone is classified as a synthetic glucocorticoid. Glucocorticoids belong to the broader chemical family known as corticosteroids and are compounds that mimic the action of natural adrenal hormones. The product's positioning as a veterinary medicine distinguishes it from similar human formulations, reflecting its specialized development for animal physiology and conditions. Being a systemically acting agent, Dermipred is designed for absorption into the bloodstream, where it circulates throughout the body to exert its effects, differentiating it from localized or topical treatments.

Composition and Therapeutic Rationale

The active compound in this single-ingredient product is prednisolone, a synthetic compound derived from precursors such as prednisolone acetate. The final presentation combines the active substance with solid pharmaceutical excipients necessary to form the final tablet dosage form. The formulation is engineered to achieve two primary pharmacological actions: powerful anti-inflammatory action and crucial immunosuppressive action. These agents are vital for their effectiveness in suppressing excessive immune activity.

The Core Benefit of Glucocorticoid Action

The general therapeutic purpose of Dermipred is to provide significant relief from the physical symptoms of severe, pathological systemic inflammation and abnormal immune overreaction. A typical use scenario involves the management of acute flare-ups of inflammatory dermatitis, where rapid reduction of inflammation is paramount. By suppressing inflammatory pathways, the drug helps to control conditions driven by an overactive or misdirected immune system. This clinically recognized mechanism is fundamentally utilized to quickly stabilize the subject and control intense discomfort associated with acute allergic and immune-mediated flare-ups.

What side effects are possible with Dermipred?

Adverse Reactions and Safety Profile

Dermipred, containing prednisolone, is associated with a wide range of side effects stemming from its glucocorticoid activity. The most Very Common adverse reactions observed, particularly during the initial stages of therapy or following withdrawal, include the suppression of the hypothalamic-pituitary-adrenal (HPA) axis, leading to hypocortisolaemia/hypoadrenocorticism, and metabolic changes such as elevated triglycerides.

Frequency Category Examples of Adverse Reactions (System-Organ Class)
Very Common Hypocortisolaemia, elevated triglycerides
Very Rare Iatrogenic Cushing's disease, diabetes mellitus, elevated liver enzymes (ALP)
Undetermined Gastrointestinal ulceration, pancreatitis, muscle wasting, osteoporosis, skin thinning, increased susceptibility to infection

Serious adverse reactions reported include gastrointestinal ulceration, which is exacerbated by concomitant use with Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and the potential development of iatrogenic hyperadrenocorticism (Cushing's syndrome). Long-term use or abrupt cessation may lead to acute adrenal insufficiency, posing a risk in stressful situations. Safety monitoring is crucial for long-term use due to the risks of osteoporosis and immunosuppression.

Safety Restrictions and Contraindications

This medication is contraindicated in individuals with systemic fungal or viral infections not controlled by specific treatment, diabetes mellitus, hyperadrenocorticism, heart failure, and gastrointestinal ulceration. Use requires caution in pregnant individuals and those with renal insufficiency, hypertension, or epilepsy. Abrupt discontinuation, particularly after prolonged use, is strongly advised against, and a gradual reduction in dosage is necessary to minimize the risk of secondary adrenal insufficiency.

Overdose and Emergency Response

Prednisolone overdose is officially described by regulatory documents through a cluster of potential systemic manifestations, particularly following chronic high-dose exposure. The documented physiological systems affected include the Gastrointestinal system, with risks such as peptic ulceration, potentially leading to hemorrhage or perforation. The Cardiovascular and Metabolic systems are also affected, manifesting as salt and water retention, hypertension, and hyperglycemia. Additionally, Neuropsychiatric changes are documented, including convulsions (seizures), psychosis, and mood swings. The official risk profile includes the potential for severe adrenocortical insufficiency after rapid cessation from chronic high-dose exposure.

Category Official Regulatory Statement
Immediate Action Management is symptomatic and supportive; contact emergency services or a poison control helpline.
Urgent Help Trigger Immediate medical attention is required for life-threatening symptoms, such as seizures, trouble breathing, or signs of gastrointestinal bleeding.
Antidote Status No specific antidote is known.

The overdose profile also notes specific considerations, such as the increased incidence of side effects in geriatric patients and the risk of growth suppression in young subjects with prolonged high-dose exposure. Hospital monitoring of vital signs and blood sugar is officially described as a necessary procedure. The regulatory documentation strictly limits the response to supportive care due to the lack of a specific antidote.

Therapeutic Uses of Dermipred

What Dermipred Treats: Main Uses and Benefits

Dermipred is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed. This medication is commonly used to help manage symptoms related to acute inflammatory and immune-mediated conditions.

The drug is commonly used for managing symptoms related to inflammatory dermatitis and severe immune-mediated skin disorders. It is also considered relevant for easing symptoms in systemic autoimmune diseases, addressing severe allergic crises, and is applied in conditions involving endocrine deficiencies (like Addison's disease).

“It is applied in clinical settings that involve acute or unstable symptom patterns, when short-term symptomatic assistance is needed.”

This approach provides support that helps ease the overall symptom burden of intense manifestations like symptoms related to physical discomfort (pruritus, erythema, and swelling). It contributes to improved comfort during periods of heightened symptoms, and assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Severe Inflammatory Symptoms

Category Description
Primary Focus Conditions involving inflammatory or irritative states
Symptom Goal Helps address symptoms that become more disruptive during flare-ups
Main Benefit Supports the patient during difficult episodes by easing distress

Regulatory References

  1. UK Veterinary Medicines Directorate Product Information

Eligibility and Restrictions for Use

Dermipred (prednisolone) is a corticosteroid medication, primarily used in veterinary medicine, specifically for dogs, to manage inflammatory and immune-mediated dermatitis (skin conditions).


Who Can Use Dermipred?

This medication is indicated for dogs requiring symptomatic or adjuvant treatment for various forms of inflammatory dermatitis and immune system-mediated dermatitis. Its use is determined by a veterinarian who weighs the potential benefits against the risks for the individual animal.


Who Cannot Use Dermipred? (Contraindications)

Dermipred should generally not be used in animals with certain pre-existing conditions, as the active ingredient, prednisolone, can worsen them or interfere with the immune response. Contraindications typically include:

  • Active Infections: Uncontrolled viral, fungal (mycotic), or parasitic infections.
  • Metabolic Disorders: Diabetes mellitus or hyperadrenocorticism (Cushing's disease).
  • Gastrointestinal Issues: Gastrointestinal or corneal ulceration.
  • Cardiac and Renal Disease: Heart failure or severe renal insufficiency.
  • Skeletal/Ocular Issues: Glaucoma or osteoporosis.
  • Allergies: Known hypersensitivity to prednisolone, other corticosteroids, or any excipients.

It is also not recommended for use in pregnant or lactating animals, as it may cause fetal abnormalities or inhibit growth in suckling young.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Dermipred (prednisolone) are documented in regulatory labeling and primarily involve two categories: alterations in drug concentration and pharmacodynamic (effect-based) synergy.

Pharmacokinetic Interactions (Drug Concentration)

Dermipred's levels in the body are significantly affected by substances that modify the CYP3A4 enzyme in the liver. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) can decrease prednisolone plasma levels, potentially reducing its effectiveness. Conversely, CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase prednisolone levels, raising the risk of systemic effects.

Pharmacodynamic Interactions (Effect-Based)

Interacting Product Category Resulting Pharmacodynamic Effect
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of gastrointestinal ulceration and bleeding.
Diuretics (Potassium-depleting) Increased risk of hypokalemia (low potassium).
Antidiabetic Agents Prednisolone may reduce the glucose-lowering effect of antidiabetic drugs (e.g., insulin), requiring careful monitoring.
Live Vaccines Co-administration is generally restricted due to the potential for immunosuppression to impair vaccine efficacy and increase infection risk.

Other Documented Interactions

Antacids may decrease prednisolone absorption, and separation of doses should be considered. Estrogens (including oral contraceptives) may increase the effects of corticosteroids, necessitating monitoring.

Mechanism of Action

How Dermipred Works

The mechanism of action for prednisolone (Dermipred) is centered on the sustained modulation of inflammatory and immune pathways at the molecular level. This action is initiated by the drug acting as an agonist, binding to the intracellular Glucocorticoid Receptor ( GR), which then translocates to the cell nucleus to alter gene expression.

This genomic modulation operates via two primary methods: it decreases the expression of genes for pro-inflammatory mediators (via transrepression of factors like NF-kappa B) and increases the expression of genes for anti-inflammatory proteins (via transactivation). This targeted genetic interference modulates the overall output of the inflammatory cascade.

A key consequence of transactivation is the increased production of proteins like Annexin A1, which indirectly inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the release of Arachidonic Acid—the precursor for prostaglandins and leukotrienes—is suppressed, acting as an early inhibition point in the pathway.

At a cellular level, prednisolone's mechanism modulates the physiological function of immune cells, limiting the ability of T-lymphocytes to proliferate and adjusting the signaling required for leukocyte migration into tissues. This systemic effect ultimately modulates the infiltration of immune cells, adjusting the physiological magnitude and duration of the body's immune responses.

Dosage and Administration Information

How to Use Dermipred

Dermipred, a medicine containing prednisolone, is administered exclusively via the oral route as tablets, which are available in 5 mg, 10 mg, and 20 mg strengths. Instructions require the dose to be calculated based on the patient's bodyweight and the specific therapeutic purpose, emphasizing precise administration.

Official Dosing Regimens and Schedule

The starting dosage is determined by the required action, and the dose must be taken twice daily (BID) during the initial phase of treatment.

Therapeutic Aim Starting Dose (per kg bodyweight) Initial Frequency
Anti-inflammatory 0.5 mg Twice Daily
Immunosuppressive 1 to 3 mg Twice Daily

For accurate titration, the tablets are scored, enabling their division into two or four equal parts to precisely meet the mg/kg requirement. Any unused portion of a divided tablet must be returned to the blister pack and carton for the next dosing time.

Course Duration and Withdrawal Protocol

The overall use protocol mandates a gradual withdrawal. Once the initial treatment goal is achieved, the dosage must be reduced gradually to the lowest effective dose. This tapering phase may incorporate alternate-day therapy as a means to manage the reduction process. Labeling advises special monitoring for patients presenting with renal insufficiency, and caution is noted for treating old or malnourished patients. These procedural steps define the structured approach for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dermipred (Prednisolone)

The available research for Dermipred's active component, prednisolone, is structured around studies in two key clinical areas. The available research includes formal randomized controlled trials (RCTs), comparative studies, and analyses of clinical data. This overview summarizes the structure of the existing research without providing clinical advice or treatment recommendations.


Evidence for Use in Acute Inflammatory Dermatitis and Allergic Skin Disorders

Research has explored the evaluation of prednisolone in contexts characterized by fluctuating or episodic manifestations, such as conditions involving acute allergic dermatitis and pruritus (itching). Studies conducted during periods of increased symptom activity have been used in research exploring how symptoms change over time.

The available evidence includes short-term Randomized Controlled Trials (RCTs) and controlled studies. Researchers examined outcomes related to physical discomfort, such as the severity of itching and the appearance of skin lesions. Findings describe patterns observed in the studies related to outcomes measured over the short duration of the trials. Studies reported on outcomes monitored during the study period, particularly those related to the severity of acute inflammatory and irritative states.

What remains uncertain relates to outcomes following the conclusion of these trials. The follow-up durations were limited, typically lasting only a few weeks to a couple of months, meaning there is limited information for long-term outcomes.


Evidence for Use in Severe Systemic Immune-Mediated Diseases

Research for severe systemic immune-mediated diseases, such as immune-mediated polyarthritis (IMPA) or immune-mediated hemolytic anemia (IMHA), is based on a mix of smaller RCTs, retrospective studies, and case series. Research examined outcomes related to systemic or functional imbalance, specifically monitoring remission rates and tracking recurrence frequency.

Data show patterns related to remission and survival within the clinical cohorts that were studied. This research contributes to understanding symptom patterns observed during study periods involving the drug.

The certainty remains low across this area compared to acute inflammatory studies. The research base contains a limited number of large-scale prospective RCTs for monotherapy. Instead, evidence quality varies across studies, with a significant amount of data coming from retrospective analyses.


What is Still Uncertain or Requires Further Research

Studies help show what has been observed so far, but evidence also indicates several areas where certainty remains low. Comparative evidence is lacking in some areas, particularly concerning large, prospective trials evaluating prednisolone monotherapy against an inactive agent for severe systemic diseases.

Furthermore, while findings describe patterns observed in studies, there is a clear limitation regarding the duration of follow-up for acute conditions. Research is ongoing to better characterize long-term outcomes, contributing to the broader evidence landscape.

Key Studies & References

  1. UK Veterinary Medicines Directorate Product Information (Dermipred)
  2. A Pilot Randomized Trial to Compare Polyuria and Polydipsia during a Short Course of Prednisolone or Methylprednisolone in Dogs with Atopic Dermatitis

Frequently Asked Questions (FAQ)

Common questions about Dermipred (FAQ)

Q: Does Dermipred cause weight gain in most people?

A: Official information indicates that corticosteroids like the active ingredient in Dermipred can affect the body's metabolism and cause changes such as increased appetite and weight gain.

Q: What should I do if I miss a dose of Dermipred?

A: Official patient information generally suggests that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued. Taking extra doses to compensate for a missed dose is generally not advised.

Q: Can you take Dermipred on an empty stomach?

A: To help minimize the risk of stomach irritation, official information often suggests that the medication be taken with food.

Q: Are there any specific foods to avoid while on Dermipred?

A: Due to the effect of corticosteroids on the body's electrolytes, dietary adjustments, such as salt restriction and potassium supplementation, may be discussed by a medical professional, particularly when higher doses are used.

Q: Does Dermipred interact with common pain relievers like ibuprofen?

A: Yes, regulatory documents indicate that using corticosteroids alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen, increases the risk of gastrointestinal ulceration and bleeding.

Q: Can Dermipred be taken with common cold and flu medications?

A: The active ingredient in Dermipred interacts with many other substances, including NSAIDs and those that affect the CYP3A4 enzyme in the liver. A healthcare professional should be consulted to check for specific interactions with any over-the-counter cold and flu medications.

Q: Is it normal to feel more energetic when taking Dermipred?

A: According to official adverse reaction reports, corticosteroids can cause psychic disturbances, including euphoria or changes in mood and behavior, which may sometimes be perceived as having increased energy.

Q: Why do doctors prescribe Dermipred for non-skin conditions?

A: Prednisolone is indicated for many conditions beyond skin issues, including Rheumatic Disorders, severe Allergic States (like asthma), Respiratory Diseases, and certain Hematologic Disorders, due to its anti-inflammatory and immunosuppressive effects.

Q: What are the signs of an allergic reaction to Dermipred?

A: While rare, official information notes that adverse reactions to the medication can include severe anaphylactic or hypersensitivity reactions, such as hives (urticaria).

Q: Can Dermipred affect your mood or cause sleeplessness?

A: Yes, regulatory information states that corticosteroids may cause psychic derangements. This can manifest as mood swings, anxiety, irritability, depression, and difficulty sleeping (insomnia).

Q: Is Dermipred safe for older adults (seniors)?

A: Official product information notes that caution is needed for use in old or malnourished patients, as special monitoring considerations are relevant.

Q: How long does Dermipred stay in your system after stopping it?

A: The active component, prednisolone, has an estimated elimination half-life of 2 to 4 hours in the blood. However, its full therapeutic actions, particularly the suppression of the body's natural adrenal response, can persist for a much longer period.

Q: Are there generic versions of Dermipred available?

A: Yes. While Dermipred is a specific brand name, its active ingredient, prednisolone, is available globally as a widely used and prescribed generic drug.

Q: What should I tell my dentist before a procedure if I'm taking Dermipred?

A: Official information generally advises that the care team, including dentists, be informed if a corticosteroid has been taken within the last twelve months. This is especially relevant before undergoing surgery or a medical procedure.

Q: Is hair loss a common side effect of Dermipred?

A: Official information on adverse dermatologic reactions includes possible thinning of the scalp hair, along with the thinning and fragility of the skin.

Q: How long is a typical treatment course with Dermipred?

A: The required duration of treatment can vary widely based on the specific condition being managed. It can range from a short course lasting only a few days to a long-term regimen over several weeks or months.

Q: How often is Dermipred usually taken per day?

A: Official prescribing information indicates that for the initial phase of treatment, the medicine is typically administered twice daily. The frequency may be reduced later during the tapering phase, sometimes involving alternate-day therapy.

Q: Does sun exposure become risky while taking Dermipred?

A: Corticosteroids can lead to thinning of the skin. This physical change may make the skin more susceptible to sun damage and increase the risk of sunburn.

Q: Are there any known withdrawal symptoms when stopping Dermipred?

A: Regulatory documents warn that abruptly stopping the medication may be associated with symptoms of withdrawal, such as severe tiredness, weakness, body aches, and joint pain. This is why a gradual reduction in dosage is necessary.

Q: Can men and women take the same dose of Dermipred?

A: Dosage requirements for prednisolone are highly individualized and determined by factors such as body weight, the specific medical condition, and the patient's response to therapy, not explicitly by sex.

Q: What visual disturbances, if any, are associated with Dermipred use?

A: The medication is associated with potential ophthalmic side effects, including the formation of posterior subcapsular cataracts and elevated pressure within the eye, known as glaucoma.

Q: What is the recommended storage temperature for Dermipred tablets?

A: Prednisolone oral tablets should generally be kept at Controlled Room Temperature, which is officially defined as being between 20 C to 25 C (68 F to 77 F).

Q: Does Dermipred affect fertility or hormones?

A: Official product information notes that corticosteroids can cause menstrual irregularities and is restricted or requires extreme caution during pregnancy or lactation due to potential endocrine effects.

Q: What are the less common, but serious, side effects of Dermipred?

A: Less common or serious effects, as noted in official reports, include the potential for gastrointestinal ulceration, the development of severe diabetes mellitus, and the risk of acute adrenal insufficiency if the medication is stopped suddenly.

Q: Can children take Dermipred, and if so, is the dosage different?

A: Prednisolone is indicated for use in the pediatric population for various medical conditions. The dosage required for children is individualized based on factors such as body weight and the medical condition being treated.

Q: Is Dermipred used for asthma or just skin inflammation?

A: The medicine is indicated for managing severe allergic conditions, including Bronchial Asthma, in addition to treating various forms of dermatitis and skin inflammation.

Q: What is the role of Dermipred in treating autoimmune flare-ups?

A: Due to its powerful immunosuppressive action, the medicine is indicated as adjunctive therapy for short-term administration. Its role is to help stabilize the patient and control acute episodes or exacerbations of autoimmune diseases.

How should Dermipred be stored and disposed of?

How to Store and Dispose of Dermipred?

Official regulatory guidelines dictate specific requirements for the storage and disposal of Dermipred tablets. Strict adherence to these conditions is necessary to maintain product stability and ensure household safety.


Storage Requirements

Requirement Rule
Temperature Do not store the product above 30 C.
Children's Safety Keep tablets out of the sight and reach of children.
Animal Safety Store out of the reach of animals due to the tablets being flavored.
Packaging Integrity Any unused tablet portion must be returned to the original blister and used for the next scheduled dose.
Stability Do not use the veterinary medicinal product after the expiry date (EXP) on the carton.

Disposal Instructions

Disposal of unused or expired Dermipred must follow official regulatory mandates. The product should not be disposed of via wastewater, such as pouring it down the sink or flushing it down the toilet. All unused medicine and waste materials must be disposed of in accordance with national requirements for veterinary medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dermipred found in:

A-Z Index: